about
Structural Plasticity of Malaria Dihydroorotate Dehydrogenase Allows Selective Binding of Diverse Chemical ScaffoldsPlasmodium falciparum PfSET7: enzymatic characterization and cellular localization of a novel protein methyltransferase in sporozoite, liver and erythrocytic stage parasitesComprehensive histone phosphorylation analysis and identification of Pf14-3-3 protein as a histone H3 phosphorylation reader in malaria parasitesExonuclease-mediated degradation of nascent RNA silences genes linked to severe malariaHigh-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compoundsSmall-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparumHistone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humansOriginal 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures.Actions of S-nitroso N-acetyl penicillamine and 3-morpholinosydonimine may involve disparate signaling pathways in myometrial smooth muscle.Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.Dissociation of cGMP accumulation and relaxation in myometrial smooth muscle: effects of S-nitroso-N-acetylpenicillamine and 3-morpholinosyndonimine.Regulation of surface coat exchange by differentiating African trypanosomesSecretion of a nucleoside diphosphate kinase (Nm23-H2) by cells from human breast, colon, pancreas and lung tumors
P50
Q27656755-C05E0E05-FF31-425E-9680-371E1B8A2EEDQ27973726-34687338-8CEF-4A95-A630-1DCF3F1A4F40Q27973893-DECD8A6C-AFB7-4815-AE44-76C51639F5E6Q27974805-B3CFC3F1-9940-4D18-B505-A06AEF876BC5Q31156888-EF0B747D-3CDF-461D-908E-729838E9C63CQ33844680-7290C67F-7E99-4796-814B-DBCC67283227Q34254755-1931E852-10C6-4C52-8B41-ACEB8F409CCAQ34421556-53558948-DD23-47F0-8368-A7C20F4FC645Q35105899-4574A045-37FD-4386-8C5F-C4AEACDB78B5Q35892823-5B2DBBEC-0244-4C17-86F5-336D746DA11CQ37057973-89DF4785-8C57-4C2E-BC6F-26BD1870D682Q38969741-B4AAFBE4-5FC1-43FB-95CB-FE2C3D255231Q43856452-EEC4394A-C0BE-4932-AAC6-01305B4119ABQ44110006-BFEE1A27-40EB-4C4F-8E48-E8D769CA3AECQ44462371-38257e22-4324-30b6-850a-41fa9a0bf4a1Q58423224-D1C2676F-63B6-4044-8B20-FAB7B7D9F430Q77496976-6CE75D42-B3A5-4470-B667-0549222FD889
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicholas A Malmquist
@ast
Nicholas A Malmquist
@en
Nicholas A Malmquist
@es
Nicholas A Malmquist
@nl
Nicholas A Malmquist
@sl
type
label
Nicholas A Malmquist
@ast
Nicholas A Malmquist
@en
Nicholas A Malmquist
@es
Nicholas A Malmquist
@nl
Nicholas A Malmquist
@sl
prefLabel
Nicholas A Malmquist
@ast
Nicholas A Malmquist
@en
Nicholas A Malmquist
@es
Nicholas A Malmquist
@nl
Nicholas A Malmquist
@sl
P106
P21
P31
P496
0000-0003-2822-8245